Nov 18 (Reuters) – Pfizer said on Wednesday it had struck an exclusive licensing agreement with China’s Starna Therapeutics to develop three CAR-T therapies for autoimmune diseases, in a deal worth up to $2.6 billion.
The deal marks another bet on a Chinese biotech by the pharma major as it seeks to reignite growth by 2028 while preparing for a wave of patent expirations and continued declines in COVID-related revenue.
• Pfizer will pay Starna $330 million upfront and could pay up to $2.3 billion more if the treatments meet development, regulatory and sales milestones. The therapies have not yet entered human trials
• Starna would also receive royalties on sales of any approved products
• The agreement gives Pfizer rights to develop and commercialize three early-stage autoimmune disease programs outside Greater China, with initial clinical trial supplies to be manufactured at its US facilities
• In vivo CAR-T therapies are designed to genetically reprogram immune cells directly inside the body, allowing them to target and eliminate disease-causing immune cells
• By contrast, conventional CAR-T treatments involve the complex process of collecting and re-engineering a patient’s cells outside the body before reinfusing them
• The deal follows Pfizer’s $10.5 billion agreement with Innovent Biologics in May and an earlier deal with China’s 3SBio in 2025
(Reporting by Padmanabhan Ananthan in Bengaluru)

